Skip to main content
Clinical Trials/NCT04240366
NCT04240366
Recruiting
Not Applicable

Additional Left Atrial Appendage Isolation During Balloon Ablation for Persistent or Long-standing Persistent Atrial Fibrillation

University of Luebeck0 sites350 target enrollmentStarted: December 17, 2019Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
University of Luebeck
Enrollment
350
Primary Endpoint
Time until any documented episode of ATa

Overview

Brief Summary

Additional left atrial appendage isolation during balloon ablation for persistent or long-standing persistent atrial fibrillation can reduce atrial fibrillation reoccurrence within 3-12 months compared to balloon-based pulmonary vein isolation only.

Detailed Description

The intervention in the LALA-LAND-AF trial is the additional LAAI in patients with catheter ablation for persistent AF and will be performed once as index ablation as outlined above. With exception of the index ablation, all patients will be treated according to the current clinical practice guidelines for AF as stated by the European Society of Cardiology (ESC) 11,18 and an expert consensus statement on catheter and surgical ablation1. Patients may be treated with a specific antiarrhythmic drug (AAD) for a maximum of 3 months following the index ablation. No repeat ablation for AF should be performed within the first 3 months. Thereafter, repeat ablations are permitted for recurrent AF irrespective of group allocation. Ablation strategy at repeat ablation includes PV re-isolation if required in both groups and re-isolation of the LAA in the intervention group. In the control group, LAAI may only be performed in case all PV were isolated.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Persistent or long-standing persistent AF (i.e. continuous AF that was/is sustained \>7 days or \>12 months, respectively)
  • Age ≥18 and ≤80 years
  • Indication for AF ablation as per current guidelines

Exclusion Criteria

  • Missing informed consent
  • LAA diameter \>25mm 10mm distant from circumflex artery assessed by TEE
  • Paroxysmal atrial fibrillation
  • Long-standing persistent atrial fibrillation with a continuous AF duration of \>4 years
  • Previous pulmonary vein isolation or MAZE surgery
  • Previous led atrial appendage closure or surgical excision
  • Left atrial diameter \>60 mm at baseline
  • Left atrial thrombus at baseline

Outcomes

Primary Outcomes

Time until any documented episode of ATa

Time Frame: 3 - 12 months

Time until any documented episode of atrial tachyarrhythmia (ATa: atrial fibrillation or atrial tachycardia) lasting longer than 30 seconds within 3-12 months after index ablation without antiarrhythmic therapy

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
University of Luebeck
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Prof. Roland Richard Tilz

Head of Electrophysiology Department

University of Luebeck

Similar Trials